Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA

Dec 2 (Reuters) - The U.S Food and Drug Administration said on Friday it had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes.